학술논문
Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab
Document Type
article
Author
Source
Dermatology Online Journal. 26(1)
Subject
Language
Abstract
Switching of biologic agents in treatment of plaque psoriasis is a common strategy. Only a few studies are available on switching between IL17A-blockers. In a retrospective study, we identified 22 psoriasis patients who, after failing secukinumab as a first IL17A-blocker received ixekizumab with an observation period of at least 24 weeks. At last observation 10/22 patients had a good response (PASI75 or PASI